{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:16:52Z","timestamp":1782325012111,"version":"3.54.5"},"reference-count":167,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.semnephrol.2014.04.006","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T12:41:04Z","timestamp":1397824864000},"page":"307-322","source":"Crossref","is-referenced-by-count":20,"title":["Aldosterone Blockade in Chronic Kidney Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Jamie S.","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2014.04.006_bib1","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/snep.2001.26797","article-title":"Aldosterone in progressive renal disease","volume":"21","author":"Hostetter","year":"2001","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib6","first-page":"337","article-title":"clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib7","first-page":"1","article-title":"clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib11","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/ndt\/gfp256","article-title":"Aldosterone in clinical nephrology--old hormone, new questions","volume":"24","author":"Becker","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib12","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib13","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib17","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1291\/hypres.27.303","article-title":"Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status","volume":"27","author":"Sato","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-005-2346-0","article-title":"Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation","volume":"10","author":"Joffe","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","article-title":"Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress","volume":"50","author":"Nagase","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.CIR.0000135599.33787.CA","article-title":"Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways","volume":"110","author":"Mano","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.yjmcc.2005.04.001","article-title":"Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo","volume":"39","author":"Burniston","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib26","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1152\/ajprenal.00147.2006","article-title":"Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity","volume":"292","author":"P\u00e9rez-Rojas","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/HYPERTENSIONAHA.107.104901","article-title":"Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate\/salt-induced tubulointerstitial fibrosis","volume":"51","author":"Iwazu","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib34","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib35","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib36","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/ndt\/gfp371","article-title":"Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes","volume":"24","author":"Nemeth","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib38","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production","volume":"26","author":"Toyonaga","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3317\/jraas.2007.014","article-title":"Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats","volume":"8","author":"Yuan","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib40","doi-asserted-by":"crossref","first-page":"e39938","DOI":"10.1371\/journal.pone.0039938","article-title":"Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats","volume":"7","author":"Banki","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.ki.5000438","article-title":"Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats","volume":"70","author":"Han","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfn448","article-title":"Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats","volume":"24","author":"Kang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2014.04.006_bib44","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1440-1797.2005.00455.x","article-title":"Role of aldosterone in diabetic nephropathy","volume":"10","author":"Cha","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/hr.2013.45","article-title":"Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults","volume":"36","author":"Cooper","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.HYP.0000105624.68174.00","article-title":"Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration","volume":"43","author":"de Paula","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib47","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1291\/hypres.27.971","article-title":"Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis","volume":"27","author":"Asai","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib49","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00524.2007","article-title":"Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome","volume":"294","author":"Nakhoul","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ndt\/gft041","article-title":"Vascular calcification--is aldosterone a culprit?","volume":"28","author":"Lang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib52","first-page":"812","article-title":"Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice","volume":"123","author":"Voelkl","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib53","doi-asserted-by":"crossref","first-page":"C788","DOI":"10.1152\/ajpcell.00407.2006","article-title":"Rapid effects of aldosterone on clonal human vascular smooth muscle cells","volume":"292","author":"Gros","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib54","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","article-title":"Nongenomic vascular action of aldosterone in the glomerular microcirculation","volume":"14","author":"Arima","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib55","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone","volume":"293","author":"Bobadilla","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib57","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"P\u00e9rez-Rojas","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib58","doi-asserted-by":"crossref","first-page":"F932","DOI":"10.1152\/ajprenal.00252.2009","article-title":"Adrenalectomy prevents renal ischemia-reperfusion injury","volume":"297","author":"Ram\u00edrez","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib59","doi-asserted-by":"crossref","first-page":"F78","DOI":"10.1152\/ajprenal.00077.2007","article-title":"Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone","volume":"293","author":"Mej\u00eda-Vilet","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib60","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/ndt\/gfs014","article-title":"Recovery from ischemic acute kidney injury by spironolactone administration","volume":"27","author":"S\u00e1nchez-Pozos","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","author":"Barrera-Chimal","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib62","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1681\/ASN.V73437","article-title":"Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease","volume":"7","author":"Dworkin","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib63","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00386.2003","article-title":"Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet","volume":"286","author":"Wang","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib64","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1161\/01.CIR.98.23.2621","article-title":"Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats","volume":"98","author":"Yu","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00004872-199917070-00008","article-title":"High salt intake potentiates the renal vascular and glomerular damage caused by low doses of angiotensin II in uni-nephrectomized rats","volume":"17","author":"Hirawa","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib66","doi-asserted-by":"crossref","first-page":"F1402","DOI":"10.1152\/ajprenal.00691.2010","article-title":"Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats","volume":"300","author":"Kawarazaki","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib67","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2796.2004.01390.x","article-title":"Sodium intake affects urinary albumin excretion especially in overweight subjects","volume":"256","author":"Verhave","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib68","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","article-title":"Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample","volume":"69","author":"Fox","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib69","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000057385","article-title":"Salt intake and renal outcome in patients with progressive renal disease","volume":"24","author":"Cianciaruso","year":"1998","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib70","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","article-title":"Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension","volume":"51","author":"Pimenta","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib71","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib72","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.HYP.0000063885.48344.EA","article-title":"Dietary salt regulates renal SGK1 abundance: relevance to salt sensitivity in the Dahl rat","volume":"41","author":"Farjah","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrneph.2012.282","article-title":"Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease","volume":"9","author":"Nagase","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib74","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib75","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1681\/ASN.2011070734","article-title":"Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation","volume":"23","author":"Kawarazaki","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib76","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ki.1978.114","article-title":"Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure","volume":"14","author":"Berl","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib77","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hen\u00e9","year":"1982","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib78","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/archinte.1986.00360230061010","article-title":"Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction","volume":"146","author":"Reams","year":"1986","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000334161","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"33","author":"Bomback","year":"2012","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib80","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/07435809809032689","article-title":"Aldosterone in obesity","volume":"24","author":"Goodfriend","year":"1998","journal-title":"Endocr Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000209744","article-title":"Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review","volume":"30","author":"Bomback","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib82","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ajh.2012.47","article-title":"Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment","volume":"25","author":"Sarzani","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib83","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1470320309352353","article-title":"Disordered aldosterone-volume relationship in end-stage kidney disease","volume":"10","author":"Bomback","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib85","doi-asserted-by":"crossref","first-page":"e57511","DOI":"10.1371\/journal.pone.0057511","article-title":"Aldosterone and mortality in hemodialysis patients: role of volume overload","volume":"8","author":"Hung","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"13","author":"Volk","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000167016","article-title":"Extracellular volume and aldosterone interaction in chronic kidney disease","volume":"27","author":"Klemmer","year":"2009","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib88","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2010.46","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib89","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/hr.2009.86","article-title":"Mineralocorticoid receptor activation in obesity hypertension","volume":"32","author":"Nagase","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib90","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib91","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/MNH.0b013e3283312fc8","article-title":"Benefits of dietary sodium restriction in the management of chronic kidney disease","volume":"18","author":"Krikken","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","article-title":"Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats","volume":"40","author":"Naruse","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib93","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","article-title":"Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy","volume":"6","author":"Bomback","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib94","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib95","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib96","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib97","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure","volume":"2","author":"Struthers","year":"1996","journal-title":"J Card Fail"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib98","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","article-title":"RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease","volume":"5","author":"Lakkis","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib99","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib102","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib103","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib104","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease","volume":"37","author":"Shiigai","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib105","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1080\/08860220802389342","article-title":"The effects of spironolactone on nephron function in patients with diabetic nephropathy","volume":"30","author":"Ustundag","year":"2008","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib107","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CNP72449","article-title":"Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage","volume":"72","author":"Bomback","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib110","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib112","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib113","doi-asserted-by":"crossref","first-page":"W79","DOI":"10.7326\/0003-4819-139-9-200311040-00022-w3","article-title":"Distinct responses of membranoproliferative glomerulonephritis-related proteinuria to spironolactone with and without angiotensin II blockade","volume":"139","author":"Yonemura","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib114","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10157-009-0213-3","article-title":"Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease","volume":"13","author":"Kuriyama","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib115","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","article-title":"The effect of aldosterone blockade in patients with Alport syndrome","volume":"21","author":"Kaito","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib116","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib117","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib119","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib121","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib122","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib123","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib124","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320311412811","article-title":"The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease","volume":"13","author":"Tsuboi","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib126","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfs429","article-title":"Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases","volume":"28","author":"Morales","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib128","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/08860220903216121","article-title":"Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease","volume":"31","author":"Sengul","year":"2009","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1681.2006.04390.x","article-title":"Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor","volume":"33","author":"Ogawa","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib130","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib131","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib132","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4158\/EP.14.8.985","article-title":"Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors","volume":"14","author":"Davidson","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib133","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib134","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J Invest Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib135","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib136","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib137","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib138","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib139","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib141","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/jhh.2011.60","article-title":"Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease","volume":"26","author":"Pisoni","year":"2012","journal-title":"J Human Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib142","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib143","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib144","doi-asserted-by":"crossref","first-page":"388","DOI":"10.5414\/CN106973","article-title":"Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study","volume":"76","author":"Shavit","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib145","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib146","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib147","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib148","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000100106","article-title":"Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis","volume":"27","author":"Steigerwalt","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib149","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib150","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib151","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/18.2.318","article-title":"Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis","volume":"18","author":"Fukuta","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib152","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/HJH.0b013e32835f955c","article-title":"Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients","volume":"31","author":"Flevari","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib153","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9343(03)00293-6","article-title":"Aldosterone blockade and vascular calcification in hemodialysis patients","volume":"115","author":"Nitta","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib154","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib155","first-page":"3","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib156","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib157","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib158","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1345\/aph.1R011","article-title":"Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis","volume":"46","author":"Baker","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib159","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/157340212804546134","article-title":"Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease","volume":"8","author":"Rekhtman","year":"2012","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib160","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/17.11.2035","article-title":"Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function","volume":"17","author":"Hausmann","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib161","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4943(01)00214-X","article-title":"Spironolactone therapy in older patients--the impact of renal dysfunction","volume":"35","author":"Butler","year":"2002","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib162","first-page":"1043","article-title":"Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone","volume":"68","author":"Erden","year":"2010","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib163","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib164","doi-asserted-by":"crossref","unstructured":"Momeni A, Behradmanesh MS, Kheiri S, Horestani MK. Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. J Renin Angiotensin Aldosterone Syst. 2013. Epub ahead of print.","DOI":"10.1177\/1470320313481485"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib166","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.04.006_bib167","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ncpneph1004","article-title":"Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?","volume":"5","author":"Bomback","year":"2009","journal-title":"Nat Clin Pract Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:55:11Z","timestamp":1648850111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929514000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":167,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0270929514000485"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}